• Triumph in Breast Cancer: KuDOS to Lynparza

    by Stephanie Hawthorne  |  Jun 4, 2017
    ASCO Annual Meeting 2017 - In the Plenary session, late breaking results from the Phase III OLYMPIAD trial, which evaluated Lynparza in comparison to “physician’s choice” chemotherapy (capecitabine, vinorelbine, eribulin) in 302 metastatic HER2- breast cancer patients with deleterious or suspected gBRCA mutations were presented. These results represent the first positive Phase III trial for a PARP inhibitor in breast cancer and the discussant, Dr. Allison Kurian, had an overall positive outlook stating that these results ”are practice-changing.”
  • ASCO Annual Meeting 2017 - Data were presented on LATITUDE, a randomized Phase III trial comparing Zytiga/prednisone plus androgen deprivation therapy (ADT) versus placebos plus ADT in newly-diagnosed high-risk metastatic hormone-naive prostate cancer (mHSPC). Based on these data, Zytiga will likely become the new standard of care for high-risk mHSPC patients. As the discussant, Eric Small, MD, stated, “LATITUDE was a profoundly positive study.”
  • ASCO Annual Meeting 2017 - If Lenvima is used in the first-line, will physicians need to wait to use Stivarga in the third-line setting after Nexavar is offered in the second-line? Could physicians’ preference to use first-line Nexavar and second-line Stivarga impact where Lenvima might be offered?
  • ASCO Annual Meeting 2017 - Given the hurdles, the data is only “semi-sweet”: good enough for regulatory approval, but the toxicities seen in MONARCH 2, and abemaciclib’s eventual third-to-market introduction might cause physicians to question when to offer the agent.
  • This blog reviews how laughter can be used as a tool in qualitative market research to foster connections and get deeper insights.
More than one Google Analytics scripts are registered. Please verify your pages and templates.